KR20240017000A - 가용형 clec2를 이용한 급성 뇌혈관 장애의 리스크 평가방법 - Google Patents
가용형 clec2를 이용한 급성 뇌혈관 장애의 리스크 평가방법 Download PDFInfo
- Publication number
- KR20240017000A KR20240017000A KR1020237044827A KR20237044827A KR20240017000A KR 20240017000 A KR20240017000 A KR 20240017000A KR 1020237044827 A KR1020237044827 A KR 1020237044827A KR 20237044827 A KR20237044827 A KR 20237044827A KR 20240017000 A KR20240017000 A KR 20240017000A
- Authority
- KR
- South Korea
- Prior art keywords
- acute cerebrovascular
- cerebrovascular disorder
- concentration
- patient
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 195
- 230000001154 acute effect Effects 0.000 title claims abstract description 89
- 238000000034 method Methods 0.000 title claims abstract description 71
- 102100032529 C-type lectin domain family 1 member B Human genes 0.000 title claims abstract description 59
- 238000012502 risk assessment Methods 0.000 title claims abstract description 33
- 101000942284 Homo sapiens C-type lectin domain family 1 member B Proteins 0.000 title claims abstract 14
- 230000001269 cardiogenic effect Effects 0.000 claims abstract description 52
- 210000004369 blood Anatomy 0.000 claims abstract description 44
- 239000008280 blood Substances 0.000 claims abstract description 44
- 230000000747 cardiac effect Effects 0.000 claims abstract description 42
- 208000024891 symptom Diseases 0.000 claims abstract description 30
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 90
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 89
- 101710160442 C-type lectin domain family 1 member B Proteins 0.000 claims description 45
- 239000003154 D dimer Substances 0.000 claims description 31
- 108010052295 fibrin fragment D Proteins 0.000 claims description 31
- 239000003550 marker Substances 0.000 claims description 16
- 210000004556 brain Anatomy 0.000 claims description 14
- 230000015271 coagulation Effects 0.000 claims description 14
- 238000005345 coagulation Methods 0.000 claims description 14
- 238000003018 immunoassay Methods 0.000 claims description 12
- 230000001052 transient effect Effects 0.000 claims description 10
- 206010027476 Metastases Diseases 0.000 claims description 7
- 230000009401 metastasis Effects 0.000 claims description 7
- 230000002490 cerebral effect Effects 0.000 claims description 6
- 230000000302 ischemic effect Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 claims description 4
- 206010059245 Angiopathy Diseases 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 abstract description 112
- 238000003745 diagnosis Methods 0.000 abstract description 29
- 238000003384 imaging method Methods 0.000 abstract description 17
- 238000009534 blood test Methods 0.000 abstract description 11
- 239000013589 supplement Substances 0.000 abstract description 3
- 210000001772 blood platelet Anatomy 0.000 description 58
- 206010061216 Infarction Diseases 0.000 description 31
- 230000007574 infarction Effects 0.000 description 31
- 208000007536 Thrombosis Diseases 0.000 description 30
- 238000011282 treatment Methods 0.000 description 27
- 238000005259 measurement Methods 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 13
- 239000003146 anticoagulant agent Substances 0.000 description 13
- 108010073385 Fibrin Proteins 0.000 description 12
- 102000009123 Fibrin Human genes 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000003748 differential diagnosis Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 229950003499 fibrin Drugs 0.000 description 12
- 230000010118 platelet activation Effects 0.000 description 11
- 208000006011 Stroke Diseases 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 229940127219 anticoagulant drug Drugs 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000004913 activation Effects 0.000 description 7
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 7
- 229940127218 antiplatelet drug Drugs 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 206010003658 Atrial Fibrillation Diseases 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 208000032382 Ischaemic stroke Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 206010013887 Dysarthria Diseases 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000004552 Lacunar Stroke Diseases 0.000 description 3
- 206010051078 Lacunar infarction Diseases 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 3
- 229960003856 argatroban Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 208000026762 inability to speak Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000009251 neurologic dysfunction Effects 0.000 description 3
- 208000015015 neurological dysfunction Diseases 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 208000026473 slurred speech Diseases 0.000 description 3
- 208000029257 vision disease Diseases 0.000 description 3
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 3
- 229960005080 warfarin Drugs 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 102000004211 Platelet factor 4 Human genes 0.000 description 2
- 108090000778 Platelet factor 4 Proteins 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000007213 cerebrovascular event Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000009863 secondary prevention Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 102100020970 ATP-binding cassette sub-family D member 2 Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 101000783774 Homo sapiens ATP-binding cassette sub-family D member 2 Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000004348 Perilla frutescens Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010051742 Retinal infarction Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 206010058571 Spinal cord infarction Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001426 cardiotropic effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010073651 fibrinmonomer Proteins 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229940127066 new oral anticoagluant drug Drugs 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2021-091606 | 2021-05-31 | ||
| JP2021091606 | 2021-05-31 | ||
| PCT/JP2022/022076 WO2022255348A1 (ja) | 2021-05-31 | 2022-05-31 | 可溶型ｃｌｅｃ２を用いた急性脳血管障害のリスク評価方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240017000A true KR20240017000A (ko) | 2024-02-06 |
Family
ID=84323407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237044827A Pending KR20240017000A (ko) | 2021-05-31 | 2022-05-31 | 가용형 clec2를 이용한 급성 뇌혈관 장애의 리스크 평가방법 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240264174A1 (https=) |
| EP (2) | EP4636404A3 (https=) |
| JP (1) | JPWO2022255348A1 (https=) |
| KR (1) | KR20240017000A (https=) |
| CN (1) | CN117813505A (https=) |
| WO (1) | WO2022255348A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025075139A1 (ja) * | 2023-10-06 | 2025-04-10 | Ｐｈｃ株式会社 | 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6078845U (ja) | 1983-11-04 | 1985-06-01 | ライオン株式会社 | 食用廃油固化処理用具 |
| JP2020032797A (ja) | 2018-08-28 | 2020-03-05 | スズキ株式会社 | ニーエアバッグ取付け構造 |
| JP2021003671A (ja) | 2019-06-26 | 2021-01-14 | 稔 甲斐 | 閉塞防止機能付振動篩用網及び振動篩装置 |
| JP2021060870A (ja) | 2019-10-08 | 2021-04-15 | 株式会社デンソー | 電子制御装置 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002359815A1 (en) * | 2001-12-19 | 2003-07-09 | Immunex Corporation | C-type lectin polypeptide, polynucleotide and methods of making and use thereof |
| JP2007070359A (ja) * | 2005-09-06 | 2007-03-22 | Univ Of Yamanashi | 止血疾患治療用の医薬組成物 |
| EP2269597A1 (en) * | 2009-06-22 | 2011-01-05 | CSL Behring GmbH | CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis |
| EP2272874A1 (en) * | 2009-07-10 | 2011-01-12 | CSL Behring GmbH | Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation |
| JP6078845B2 (ja) * | 2012-09-28 | 2017-02-15 | 株式会社Ｌｓｉメディエンス | 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法 |
| US10227407B2 (en) * | 2013-10-10 | 2019-03-12 | Yukinari Kato | Anti-podoplanin antibody |
| EP4113524A4 (en) * | 2020-02-28 | 2024-03-06 | LSI Medience Corporation | METHOD FOR MEASURING PLATELE ACTIVATION BASED ON SOLUBLE CLEC-2 AND PLATELE COUNT |
-
2022
- 2022-05-31 US US18/565,207 patent/US20240264174A1/en active Pending
- 2022-05-31 JP JP2023525849A patent/JPWO2022255348A1/ja active Pending
- 2022-05-31 KR KR1020237044827A patent/KR20240017000A/ko active Pending
- 2022-05-31 WO PCT/JP2022/022076 patent/WO2022255348A1/ja not_active Ceased
- 2022-05-31 EP EP25193124.2A patent/EP4636404A3/en active Pending
- 2022-05-31 EP EP22816094.1A patent/EP4350349A4/en active Pending
- 2022-05-31 CN CN202280038994.9A patent/CN117813505A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6078845U (ja) | 1983-11-04 | 1985-06-01 | ライオン株式会社 | 食用廃油固化処理用具 |
| JP2020032797A (ja) | 2018-08-28 | 2020-03-05 | スズキ株式会社 | ニーエアバッグ取付け構造 |
| JP2021003671A (ja) | 2019-06-26 | 2021-01-14 | 稔 甲斐 | 閉塞防止機能付振動篩用網及び振動篩装置 |
| JP2021060870A (ja) | 2019-10-08 | 2021-04-15 | 株式会社デンソー | 電子制御装置 |
Non-Patent Citations (3)
| Title |
|---|
| F. Kazama et al., Platelets 2015; 26(8):711-719 |
| X. Zhang et al., Stroke.2019;50:45-52. |
| Y. Yamashita et al., Thrombosis Research 178(2019) 54-58 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4636404A3 (en) | 2025-11-19 |
| CN117813505A (zh) | 2024-04-02 |
| US20240264174A1 (en) | 2024-08-08 |
| WO2022255348A1 (ja) | 2022-12-08 |
| EP4636404A2 (en) | 2025-10-22 |
| JPWO2022255348A1 (https=) | 2022-12-08 |
| EP4350349A4 (en) | 2025-04-23 |
| EP4350349A1 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4733326B2 (ja) | 患者サンプル中の止血機能障害の存在を予測する方法 | |
| JP7546037B2 (ja) | 可溶型ｃｌｅｃ－２と血小板数に基づく血小板活性化測定方法 | |
| EP2835641A1 (en) | Methods and kits for predicting the risk of having a cardiovascular disease or event | |
| Huang et al. | High concentrations of procoagulant microparticles in the cerebrospinal fluid and peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome | |
| JP2009539080A (ja) | 急性冠状動脈症候群のリスクを有する個体の識別のためのｍｒｐ８／１４レベルの使用 | |
| KR20240017000A (ko) | 가용형 clec2를 이용한 급성 뇌혈관 장애의 리스크 평가방법 | |
| EP4350350A1 (en) | Method for assessing risk of hemorrhagic stroke using soluble clec2 | |
| US12332252B2 (en) | GFAP accumulating in stroke | |
| HK40127498A (en) | Method for evaluating risk of acute cerebral vascular disease using soluble clec2 | |
| HK40105374A (en) | Method for evaluating risk of acute cerebral vascular disease using soluble clec2 | |
| KR20140023260A (ko) | Cartilage Acidic Protein 1 단백질에 의한 뇌경색의 검사 방법 | |
| JPWO2022255348A5 (https=) | ||
| JP7695113B2 (ja) | 可溶型ｃｌｅｃ２を用いたウイルス性肺炎のリスク評価法 | |
| HK40106384A (en) | Method for assessing risk of hemorrhagic stroke using soluble clec2 | |
| JP7808059B2 (ja) | 可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法 | |
| RU2789822C1 (ru) | Способ оптимизации лабораторной диагностики тромбинемии у пациентов с инфекцией COVID-19 | |
| WO2014069490A1 (ja) | サイクロフィリンａによる心血管疾患の検査方法 | |
| WO2025075139A1 (ja) | 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法 | |
| Alakraa et al. | Comparison of Platelet Activation Phenotyping Markers, Soluble Fibrin Monomer Complex and Soluble P-Selectin in Venous Thromboembolism | |
| HK40085757A (en) | Method for measuring platelet activation based on soluble clec-2 and platelet count | |
| RU2704224C1 (ru) | Способ прогнозирования мультифокального атеросклеротического поражения | |
| Hosny El-said | The association of Inflammatory markers and ICAM-1 with neurological disabilities in Relapsing Remitting Multiple Sclerosis (RRMS) patients | |
| Hsiao et al. | D-dimer assay not adequate for spontaneous intracranial hemorrhage screening | |
| Ahmed et al. | D-dimer as Sensitive parameters in COVID-19 (Study of 200 patients) | |
| Krishnamurthy | A study of serum concentration of c-reactive protein and esr in acute ischemic stroke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231226 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250307 Comment text: Request for Examination of Application |